Stock listing
gettex:BOV Apyx Medical Corporation Aktie
German listing (gettex) of Apyx Medical Corporation · home listing NASDAQ:APYX
Follow Apyx Medical Corporation into a list and get an email when it puts out news.
Home listing price · NASDAQ:APYX
$2.40 USD -0.09 (-3.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:APYX
- Day range
- $2.35 – $2.46 USDNov 20, 2026
- Volume
- 100,118 sharesNov 20, 2026
- Market cap
- $101.1M USDAt the close on Nov 20, 2026 · price × 42.12M shares outstanding
- 52-week range
- $2.25 – $5.08 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $399,125 USDMedian day 90,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:APYX · Home | $2.40 USD | -0.09 (-3.6%) | 100,118 | $2.44 | $2.46 | $2.35 | $2.49 | Close on Nov 20, 2026 |
| Frankfurt:BOV | €2.12 EUR | 0.00 (0.0%) | — | €2.10 | €2.12 | €2.10 | €2.12 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APYX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.40 | -0.09 | -3.6% | $2.44 | $2.46 | $2.35 | 100,118 | |
| $2.49 | -0.065 | -2.5% | $2.52 | $2.57 | $2.385 | 188,655 | |
| $2.555 | -0.095 | -3.6% | $2.67 | $2.67 | $2.40 | 46,115 | |
| $2.65 | -0.16 | -5.7% | $2.886 | $2.886 | $2.53 | 71,230 | |
| $2.81 | -0.08 | -2.8% | $2.795 | $2.81 | $2.66 | 43,008 | |
| $2.89 | -0.11 | -3.7% | $2.93 | $2.93 | $2.772 | 128,115 | |
| $3.00 | +0.07 | +2.4% | $3.08 | $3.096 | $2.915 | 34,178 | |
| $2.93 | -0.01 | -0.3% | $2.96 | $3.02 | $2.88 | 63,858 | |
| $2.94 | +0.01 | +0.3% | $2.96 | $3.05 | $2.92 | 72,336 | |
| $2.93 | -0.13 | -4.2% | $3.05 | $3.30 | $2.88 | 201,253 | |
| $3.06 | +0.47 | +18.1% | $2.60 | $3.107 | $2.575 | 994,628 | |
| $2.59 | -0.01 | -0.4% | $2.65 | $2.67 | $2.55 | 144,846 | |
| $2.60 | 0.00 | 0.0% | $2.59 | $2.65 | $2.57 | 64,895 | |
| $2.60 | 0.00 | 0.0% | $2.58 | $2.80 | $2.53 | 116,200 | |
| $2.60 | -0.09 | -3.3% | $2.65 | $2.65 | $2.53 | 38,090 | |
| $2.69 | +0.08 | +3.1% | $2.60 | $2.69 | $2.48 | 67,399 | |
| $2.61 | +0.11 | +4.4% | $2.53 | $2.61 | $2.515 | 34,756 | |
| $2.50 | +0.04 | +1.6% | $2.45 | $2.527 | $2.41 | 46,239 | |
| $2.46 | +0.09 | +3.8% | $2.37 | $2.47 | $2.35 | 128,806 | |
| $2.37 | -0.04 | -1.7% | $2.39 | $2.40 | $2.25 | 146,157 | |
| $2.41 | -0.10 | -4.0% | $2.46 | $2.53 | $2.34 | 187,326 | |
| $2.51 | +0.07 | +2.9% | $2.47 | $2.513 | $2.42 | 70,315 | |
| $2.44 | +0.02 | +0.8% | $2.45 | $2.56 | $2.42 | 366,566 | |
| $2.42 | -0.13 | -5.1% | $2.55 | $2.56 | $2.35 | 223,589 | |
| $2.55 | -0.01 | -0.4% | $2.60 | $2.65 | $2.54 | 54,000 | |
| $2.56 | -0.01 | -0.4% | $2.45 | $2.58 | $2.45 | 151,900 | |
| $2.57 | -0.03 | -1.2% | $2.59 | $2.59 | $2.49 | 38,700 | |
| $2.60 | -0.05 | -1.9% | $2.68 | $2.68 | $2.48 | 148,800 | |
| $2.65 | +0.06 | +2.3% | $2.62 | $2.73 | $2.53 | 80,000 | |
| $2.59 | +0.23 | +9.7% | $2.38 | $2.62 | $2.38 | 103,500 | |
| $2.36 | -0.19 | -7.5% | $2.54 | $2.54 | $2.34 | 231,400 | |
| $2.55 | +0.005 | +0.2% | $2.52 | $2.60 | $2.49 | 34,800 | |
| $2.545 | -0.055 | -2.1% | $2.63 | $2.63 | $2.53 | 129,300 | |
| $2.60 | +0.05 | +2.0% | $2.53 | $2.63 | $2.50 | 68,400 | |
| $2.55 | +0.05 | +2.0% | $2.51 | $2.60 | $2.50 | 51,700 | |
| $2.50 | +0.05 | +2.0% | $2.46 | $2.62 | $2.42 | 294,900 | |
| $2.45 | -0.15 | -5.8% | $2.58 | $2.827 | $2.45 | 639,600 | |
| $2.60 | +0.10 | +4.0% | $2.63 | $2.65 | $2.46 | 338,500 | |
| $2.50 | -0.46 | -15.5% | $2.90 | $2.95 | $2.32 | 362,300 | |
| $2.96 | +0.13 | +4.6% | $2.85 | $2.97 | $2.85 | 131,400 | |
| $2.83 | -0.12 | -4.1% | $2.96 | $2.96 | $2.83 | 73,800 | |
| $2.95 | 0.00 | 0.0% | $2.92 | $2.962 | $2.89 | 86,100 | |
| $2.95 | +0.04 | +1.4% | $2.93 | $2.98 | $2.91 | 73,900 | |
| $2.91 | -0.15 | -4.9% | $3.06 | $3.075 | $2.86 | 169,100 | |
| $3.06 | +0.03 | +1.0% | $3.03 | $3.063 | $3.00 | 152,700 | |
| $3.03 | +0.02 | +0.7% | $3.04 | $3.11 | $3.00 | 34,200 | |
| $3.01 | +0.05 | +1.7% | $2.97 | $3.075 | $2.90 | 81,000 | |
| $2.96 | -0.06 | -2.0% | $3.03 | $3.03 | $2.90 | 44,100 | |
| $3.02 | +0.12 | +4.1% | $2.88 | $3.03 | $2.875 | 89,100 | |
| $2.90 | +0.01 | +0.3% | $2.90 | $3.07 | $2.79 | 161,300 | |
| $2.89 | -0.16 | -5.2% | $3.05 | $3.07 | $2.87 | 90,900 | |
| $3.05 | 0.00 | 0.0% | $3.05 | $3.055 | $3.00 | 70,400 | |
| $3.05 | 0.00 | 0.0% | $2.97 | $3.07 | $2.97 | 128,500 | |
| $3.05 | -0.01 | -0.3% | $3.06 | $3.08 | $3.02 | 62,100 | |
| $3.06 | -0.02 | -0.6% | $3.08 | $3.08 | $2.96 | 144,000 | |
| $3.08 | +0.03 | +1.0% | $3.07 | $3.11 | $3.05 | 26,000 | |
| $3.05 | 0.00 | 0.0% | $3.07 | $3.11 | $3.01 | 100,400 | |
| $3.05 | -0.03 | -1.0% | $3.05 | $3.189 | $3.02 | 46,700 | |
| $3.08 | +0.08 | +2.7% | $3.01 | $3.22 | $3.00 | 115,300 | |
| $3.00 | -0.05 | -1.6% | $3.05 | $3.05 | $2.825 | 815,900 | |
| $3.05 | -0.06 | -1.9% | $3.12 | $3.12 | $2.99 | 116,700 | |
| $3.11 | +0.03 | +1.0% | $3.12 | $3.24 | $3.09 | 48,430 | |
| $3.08 | -0.04 | -1.3% | $3.13 | $3.19 | $2.98 | 119,571 | |
| $3.12 | +0.09 | +3.0% | $3.05 | $3.17 | $3.04 | 52,900 | |
| $3.03 | -0.12 | -3.8% | $3.15 | $3.29 | $3.03 | 88,800 |
- Ticker
- gettex:BOV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 5, 2026
Apyx Medical (NASDAQ:APYX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 20 slides
Latest news
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $3.06 (+18.1%) on Nov 5, 2026
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
Oct 22, 2026
Closed $2.41 (-4.0%) on Oct 22, 2026
Apyx Medical Corporation to Participate in Upcoming Investor Conferences
Oct 21, 2026
Closed $2.51 (+2.9%) on Oct 21, 2026
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Sep 29, 2026
Closed $2.60 (+4.0%) on Sep 29, 2026
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $4.05 (-2.6%) on Aug 7, 2026
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
Jul 28, 2026
Closed $3.86 (-0.8%) on Jul 28, 2026
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Jul 23, 2026
Closed $3.83 (-2.0%) on Jul 23, 2026
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
May 27, 2026
Closed $3.90 (-4.6%) on May 27, 2026
Apyx Medical Corporation on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 21 in the last 12 months · 109 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 31 calls with a replay · 31 with a transcript · latest Nov 5, 2026
- Decks
- 13 decks · latest November 2026
Where Apyx Medical Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:APYX · Home listing | NASDAQ | United States | USD |
| gettex:BOV · This page | gettex | Germany | EUR |
| BOATS:APYX | BOATS | United States | USD |
| LS Exchange:A2PBJC | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PBJC | Lang & Schwarz | Germany | EUR |
| Dusseldorf:BOV | Dusseldorf | Germany | EUR |
| Stuttgart:BOV | Stuttgart | Germany | EUR |
| Frankfurt:BOV | Frankfurt | Germany | EUR |
| Munich:BOV | Munich | Germany | EUR |
| Tradegate:BOV | Tradegate | Germany | EUR |
Valuation
EV/sales 1.9× against a median of 1.4×: 7th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $112.8M USD
- P/E
- Loss
- EV/sales
- 1.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.5×
- Gross margin
- 63.4%
- Operating margin
- −5.5%
- Net margin
- −14.2%
- Debt to equity
- 3.9×
- Beta vs S&P 500
- 0.85
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Apyx Medical Corporation · NASDAQ:APYX | US$101.1M | US$112.8M | n/a | 1.9× | n/a | 10.5× | −14.2% | 3.9× | 0.85 |
| Aroa Biosurgery Ltd · ASX:ARX | US$112.6M | US$101.1M | 40.9× | 1.7× | 16.9× | 2.1× | 4.5% | 0.1× | n/a |
| Pulmonx Corporation · NASDAQ:LUNG | US$111.9M | US$97.15M | n/a | 1.1× | n/a | 3.3× | −47.9% | 1.1× | 1.95 |
| Laxmi Dental Ltd. · NSE:LAXMIDENTL | US$111.4M | US$110.1M | 31.9× | 3.5× | 20.4× | 3.9× | 11.0% | 0.1× | n/a |
| Onward Medical N.V. · EURONEXT:ONWD | US$106.1M | US$31.75M | n/a | 5.3× | n/a | 1.3× | −771.8% | 0.2× | n/a |
| Interojo Inc. · KRX:119610 | US$105.7M | US$84.13M | 8.0× | 0.9× | 3.4× | 0.9× | 14.3% | 0.0× | n/a |
| Orthocell Ltd · ASX:OCC | US$102.8M | US$74.57M | n/a | 9.9× | n/a | 4.5× | −122.0% | 0.1× | n/a |
| Sisram Medical Ltd. · HKEX:1696 | US$101.5M | US$103.1M | 5.3× | 0.3× | 2.1× | 0.2× | 5.2% | 0.2× | n/a |
| Thai Optical Group Public Co. Ltd. · SET:TOG | US$98.05M | US$103.0M | 9.4× | 1.0× | 5.1× | 1.3× | 9.9% | 0.1× | n/a |
| Stereotaxis, Inc. · AMEX:STXS | US$94.41M | US$92.90M | n/a | 3.0× | n/a | 4.4× | −70.9% | 0.1× | 1.03 |
| Gaush Meditech Ltd. · HKEX:2407 | US$94.33M | US$101.0M | 6.5× | 0.5× | 3.2× | 0.4× | 7.0% | 0.2× | n/a |
| Median of the others | US$104.2M | US$99.07M | 8.7× | 1.4× | 4.3× | 1.7× | 4.9% | 0.1× | 1.49 |
Forecasts
4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 5 analysts
- Revenue, year to Dec 2026
- 59.59M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Charlie Goodwin | President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Andrew Makrides | Chairman of the Board |
| Stavros Vizirgianakis | Chairman of the Board |
Events
Calls
| Call | When | Status |
|---|---|---|
| Apyx Medical (NASDAQ:APYX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q4 2025 Earnings Call | Tue, Mar 10, 2026 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q4 2024 Earnings Call | Thu, Mar 13, 2025 · 8:30 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q3 2024 Earnings Call | Fri, Nov 08, 2024 · 8:00 AM ET | Replay |
| Apyx Medical (NASDAQ:APYX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 5:00 PM ET | Replay |
All 31 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | +18.1% |
| Q2 2026 | Aug 6, 2026 · After close | −2.6% |
| Q1 2026 | May 7, 2026 · Before open | +21.9% |
| Q4 2025 | Mar 10, 2026 | +14.6% |
| Q3 2025 | Nov 6, 2025 · Before open | +6.7% |
| Q2 2025 | Aug 7, 2025 · After close | +11.2% |
| Q1 2025 | May 7, 2025 · Before open | +16.8% |
| Q4 2024 | Mar 13, 2025 · Before open | −2.8% |
| Q3 2024 | Nov 8, 2024 · Before open | +24.6% |
| Q2 2024 | Aug 8, 2024 · After close | +2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +23.0% |
| Q4 2023 | Mar 21, 2024 · Before open | −28.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −20.3% |
| Q2 2023 | Aug 10, 2023 · After close | +20.1% |
| Q1 2023 | May 11, 2023 · Before open | +28.7% |
| Q4 2022 | Mar 16, 2023 · Before open | +10.7% |
| Q3 2022 | Nov 10, 2022 · Before open | −60.5% |
| Q2 2022 | Aug 11, 2022 · After close | −19.8% |
| Q1 2022 | May 12, 2022 · Before open | +7.7% |
| Q4 2021 | Mar 17, 2022 · Before open | +14.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 20 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 20 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 18 slides | May 7, 2026 |
| Investor Presentation (May 2026) | Investor deck | 18 slides | May 2026 |
| Investor Presentation (January 2026) | Investor deck | 18 slides | January 2026 |
| Investor Presentation (March 2025) | Investor deck | 24 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 24 slides | January 2025 |
| Investor Presentation (August 2024) | Investor deck | 24 slides | August 2024 |
| Investor Presentation (June 2024) | Investor deck | 25 slides | June 2024 |
| Investor Presentation (April 2024) | Investor deck | 27 slides | April 2024 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2024) | Investor deck | 28 slides | January 2024 |
| Investor Presentation (August 2023) | Investor deck | 27 slides | August 2023 |
| Investor Presentation (November 2021) | Investor deck | 27 slides | November 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or common stock equivalents) Announced: Lucid Capital Markets Dealers: Lucid Capital Markets (lead) | Nov 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.8M | 48.1M | 52.3M | 44.5M | 48.5M | 27.7M | 28.2M | 16.6M | 10.2M | 8.82M |
| Cost of revenue | 19.8M | 18.7M | 18.6M | 15.4M | 14.9M | 10.2M | 9.14M | 5.78M | 3.28M | 3.70M |
| Gross profit | 33.0M | 29.4M | 33.8M | 29.1M | 33.6M | 17.5M | 19.1M | 10.8M | 6.96M | 5.12M |
| Research and development | 3.37M | 5.08M | 5.44M | 4.54M | 4.32M | 3.92M | 3.73M | 2.55M | 1.94M | 1.03M |
| Selling, general and administrative | 15.8M | 18.9M | 22.2M | 20.5M | 18.6M | 11.7M | 13.7M | 9.41M | 8.69M | 6.18M |
| Operating income | -6.45M | -18.8M | -17.3M | -23.6M | -14.4M | -20.1M | -20.9M | -14.3M | -13.9M | -11.4M |
| Depreciation and amortization | 655.0K | 599.0K | 692.0K | 890.0K | 903.0K | 887.0K | 754.0K | 669.0K | 696.0K | 734.0K |
| EBITDA | -5.79M | -18.2M | -16.6M | -22.7M | -13.5M | -19.2M | -20.1M | -13.6M | -13.2M | -10.7M |
| Interest expense | 5.59M | 5.91M | 2.48M | 15.0K | 10.0K | 46.0K | 8.00K | 104.0K | 136.0K | 158.0K |
| Income before tax | -10.8M | -23.3M | -21.3M | -22.9M | -14.8M | -19.4M | -19.8M | -14.7M | -13.8M | -11.5M |
| Income tax | 270.0K | 252.0K | -2.43M | 367.0K | 380.0K | -7.50M | -130.0K | -3.91M | -156.0K | 64.0K |
| Net income | -11.2M | -23.5M | -18.7M | -23.2M | -15.2M | -11.9M | -19.7M | 62.7M | -5.06M | -11.6M |
| Earnings per share, basic | -0.27 | -0.66 | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.89 | -0.16 | -0.14 |
| Earnings per share, diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.83 | -0.17 | -0.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 31.7M | 31.7M | 43.7M | 10.2M | 30.9M | 41.9M | 58.8M | 16.6M | 9.95M | 14.5M |
| Short-term investments | 39.7M | 0 | 61.7M | 0 | 779.0K | |||||
| Receivables | 16.8M | 15.5M | 14.0M | 10.6M | 13.0M | 8.40M | 7.99M | 5.08M | 4.86M | 4.73M |
| Inventory | 8.60M | 7.56M | 9.92M | 11.8M | 6.78M | 4.05M | 5.07M | 5.30M | 4.27M | 6.16M |
| Current assets | 58.5M | 56.4M | 70.4M | 43.0M | 60.7M | 66.1M | 76.7M | 89.8M | 22.5M | 26.5M |
| Property, plant and equipment | 2.37M | 1.99M | 1.92M | 6.76M | 6.58M | 6.54M | 6.62M | 5.79M | 6.03M | 6.45M |
| Goodwill | 185.0K | 185.0K | 185.0K | |||||||
| Total assets | 66.8M | 64.8M | 79.2M | 51.8M | 68.7M | 74.1M | 84.7M | 95.9M | 31.0M | 35.1M |
| Accounts payable | 3.06M | 2.62M | 2.71M | 2.67M | 2.63M | 1.51M | 2.44M | 1.42M | 1.58M | 1.61M |
| Current liabilities | 11.7M | 10.7M | 12.7M | 11.8M | 13.2M | 9.15M | 12.3M | 8.61M | 5.97M | 5.27M |
| Long-term debt | 34.8M | 33.9M | 33.2M | 0 | 0 | 2.46M | 2.69M | |||
| Total debt | 37.5M | 37.5M | 33.2M | 0 | 305.0K | 676.0K | 1.13M | 0 | 2.69M | 2.93M |
| Total liabilities | 52.0M | 50.5M | 52.3M | 14.0M | 14.7M | 10.3M | 13.5M | 8.75M | 8.96M | 8.89M |
| Shareholders' equity | 14.5M | 14.2M | 26.7M | 37.6M | 53.7M | 63.7M | 71.3M | 87.2M | 22.0M | 26.2M |
| Shares outstanding | 41.8M | 37.8M | 34.6M | 34.6M | 34.4M | 34.3M | 34.2M | 33.7M | 32.9M | 30.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.00M | -18.0M | -5.25M | -20.3M | -10.4M | -16.1M | -18.5M | -20.9M | -3.70M | -2.84M |
| Capital spending | -1.11M | -722.0K | -533.0K | -1.01M | -723.0K | -581.0K | -1.30M | -363.0K | -624.0K | -286.0K |
| Free cash flow | -9.12M | -18.8M | -5.78M | -21.3M | -11.2M | -16.6M | -19.8M | -21.2M | -4.33M | -3.12M |
| Cash from investing | -1.11M | -722.0K | 6.73M | -1.01M | -723.0K | -581.0K | 60.5M | 29.3M | -624.0K | -286.0K |
| Cash from financing | 9.58M | 6.75M | 32.2M | 217.0K | 24.0K | -73.0K | 147.0K | -2.49M | -239.0K | 5.71M |
| Share buybacks | 195.0K | 148.0K | 207.0K | 202.0K | 5.83M | |||||
| Change in cash | -1.00K | -11.9M | 33.5M | -20.7M | -11.0M | -16.9M | 42.2M | 5.93M | -4.57M | 2.65M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Nov 19, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Aug 7, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 21, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jun 26, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | Jun 1, 2026 | ESG report | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Dec 17, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 1, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 17, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Aug 13, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Jun 25, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 13, 2025 | Meeting notice | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 424B5 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 31, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| DEF 14A · Proxy statement | Jun 25, 2024 | Meeting notice | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 9, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 9, 2024 | Material contract | SEC |
| SC 13D · Big-stake notice | Apr 5, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Apr 1, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 25, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 23, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 22, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 28, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Nov 16, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Nov 16, 2023 | Offer document | SEC |
| 4 · Change in ownership | Nov 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 9, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Aug 16, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 14, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jun 23, 2023 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Jun 21, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 12, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2023 | Insider trade | SEC |
| SD · Specialized disclosure | May 31, 2023 | ESG report | SEC |
| SC 13G · Big-stake notice | May 19, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 12, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 8-K · Current report | Apr 18, 2023 | Material contract | SEC |
| 4 · Change in ownership | Mar 22, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 16, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2023 | Results | SEC |
| 8-K · Current report | Mar 15, 2023 | Material contract | SEC |
| 8-K · Current report | Feb 24, 2023 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 11, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2023 | Results | SEC |
| EFFECT · Notice that a registration is effective | Dec 5, 2022 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 2, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 30, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 30, 2022 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 22, 2022 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 22, 2022 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 21, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 4 · Change in ownership | Aug 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 17, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 8-K · Current report | Jul 18, 2022 | Current report | SEC |
| 4 · Change in ownership | Jul 12, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 11, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jun 24, 2022 | Meeting notice | SEC |
| 8-K · Current report | Jun 13, 2022 | Current report | SEC |
| SD · Specialized disclosure | May 27, 2022 | ESG report | SEC |
| 8-K · Current report | May 26, 2022 | Current report | SEC |
| 4 · Change in ownership | May 23, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
This page holds 200 of 993 filings. Open Filings
Cap table
Built by 6ix from Apyx Medical Corporation’s releases · as of Nov 4, 2026
- Common shares
- 42,124,023
- Fully diluted
- 42,124,023
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 42,124,023 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 42,124,023 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Stavros G. Vizirgianakis Other companies: Xtant Medical Holdings, Inc. (Director · Since at least Aug 25, 2022); Medinotec Inc. (Director · Apr 16, 2025 – Apr 16, 2025 · Past); Bioventus Inc. (Director · Oct 29, 2021 – Jun 16, 2022 · Past); Misonix Inc (President and CEO, Director · May 7, 2013 – Oct 29, 2021 · Past) | Chairman of the Board · Since at least May 7, 2024 |
| Mathew C Hill Other companies: PDS Biotechnology Corporation (Chief Financial Officer · Oct 18, 2021 – Jan 5, 2023 · Past); STRATA Skin Sciences, Inc. (Chief Financial Officer · May 15, 2018 – Nov 13, 2020 · Past); Ep Medsystems Inc (Chief Financial Officer · Dec 12, 2006 – Dec 12, 2006 · Past) | Chief Financial Officer · Since at least Dec 4, 2023 |
| Minnie Baylor-Henry Other companies: Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022); Lantheus Holdings, Inc. (Director · Since at least May 6, 2022); Paratek Pharmaceuticals Inc (Director · Feb 8, 2023 – Sep 21, 2023 · Past) | Director · Since at least Aug 11, 2022 |
| Ian Sheffield Other companies: Invivyd, Inc. (Director · Since at least Aug 30, 2026); Fractyl Health, Inc. (Director · Since at least Sep 2, 2025) | Director · Dec 13, 2013 – May 6, 2015 · Past |
| Lawrence J. Waldman Other companies: CVD Equipment Corporation (Director · Since at least Oct 5, 2016); Comtech Telecommunications Corp. (Lead Independent Director · Since at least Aug 31, 2015) | Director · Since at least Mar 18, 2011 |
| Charles T Orsatti Other companies: Djo Inc (Director · Jun 7, 2006 – Nov 20, 2007 · Past) | Director · May 6, 2015 – Jul 28, 2016 · Past |
| Gary Pickett Other companies: First Choice Healthcare Solutions, Inc. (Chief Financial Officer · Nov 3, 2014 – Nov 3, 2014 · Past) | Chief Financial Officer · Mar 29, 2007 – Jul 12, 2012 · Past |
| Scott Richard Davidson Other companies: WaferGen Bio-systems Inc (Director · Jan 12, 2012 – Nov 15, 2013 · Past) | Director · Jul 28, 2016 – Jul 28, 2016 · Past |
| Alfred V Greco | Director · May 5, 2005 – May 12, 2005 · Past |
| Andrew Makrides | Chairman of the Board · Since at least Dec 5, 2008 |
All 29 people
| Person | Seat |
|---|---|
| August Lentricchia | Director · Aug 9, 2007 – Dec 9, 2013 · Past |
| Charles D Goodwin II | Chief Executive Officer, Director · Since at least Dec 15, 2017 |
| Charlie Goodwin | President and Chief Executive Officer · Since at least Nov 5, 2026 |
| Craig A Swandal | Director · Mar 9, 2018 – Aug 8, 2024 · Past |
| George W Kromer | Director · May 5, 2005 – Oct 1, 2013 · Past |
| Gregory Alan Konesky | Director · Dec 29, 2009 – Dec 23, 2011 · Past |
| Jay D Ewers | Chief Financial Officer · Jun 15, 2015 – Jan 4, 2018 · Past |
| John C Andres | Director · Aug 30, 2018 – Aug 8, 2024 · Past |
| John J McCarthy III | Chief CommercializationOfficer · Dec 22, 2015 – May 1, 2017 · Past |
| J Robert Saron | President, Director · Sep 19, 2014 – May 1, 2017 · Past |
| Michael Geraghty | Director · Aug 8, 2024 – Aug 8, 2024 · Past |
| Moshe Citronowicz | Sr. V.P. of Operations · Since at least Jan 1, 2008 |
| Randy D Rossi | Director · May 5, 2005 – Aug 28, 2008 · Past |
| Robert Gershon | Chief Executive Officer, Director · Dec 13, 2013 – May 1, 2017 · Past |
| Shawn David Roman | Chief Operating Officer · Since at least Nov 6, 2024 |
| Steven MacLaren | Director · Jul 8, 2010 – Jul 8, 2010 · Past |
| Tara Semb | Chief Financial Officer · Jan 2, 2019 – Jan 11, 2023 · Past |
| Todd Hornsby | Executive Vice President · Jan 6, 2019 – Jan 10, 2024 · Past |
| Wendy Lauren Levine | Director · Since at least Aug 25, 2021 |
Log in to ask 6ix AI your own questions about Apyx Medical Corporation.